NS-0100
AssetAlso called NS-0100-01, Low Metformin, Mid Metformin, High Metformin
Synergistic combination of leucine and metformin activating sirtuin and AMPK pathways to improve glycemic control.
- Stage
- Phase 2, no development reported
- Modality
- Small molecule
- Target
- Not known
- 1
- Indication
- 2
- Trials
- 1
- Developer
No development reported since January 2016. Last activity: Trial NCT02435277 completed. clinicaltrials.gov
Indications
1Type 2 diabetes
Phase 2, Completed, NCT02151461, clinicaltrials.gov, Oct 31, 2026
In the full profile
- Target and mechanism1
- Owner and partners1
- Trials2
- Evidence for its targets1
- Competitors12
- Aging relevance2
- Signals5
Every asset’s record: target, stage, trials and the evidence behind it.